{"id":"W2923800831","doi":"10.1186/s13058-019-1115-2","title":"PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Chugai Pharmaceutical; Genentech; Eisai; MacroGenics; Puma Biotechnology; Daiichi-Sankyo; Teva Pharmaceutical Industries; Wyeth; Sanofi; GlaxoSmithKline; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Neratinib; Placebo; Surgical oncology; Double blind; Medicine; Randomized controlled trial; Oncology; Internal medicine; Breast cancer; Alternative medicine; Pathology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004389116,0.001781491,0.004033231,0.0003748481,0.0003216919,0.001187547,0.0009725476,0.001497475,0.005464082],"category_scores_gemma":[0.004153768,0.0005070891,0.003328554,0.0004623274,0.001037543,0.001491557,0.0005221972,0.002215528,0.0005415577],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000598854,"about_ca_system_score_gemma":0.0007496179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002435359,"about_ca_topic_score_gemma":0.0005607223,"domain_scores_codex":[0.9983711,0.0009281568,0.0001799659,0.0002591212,0.0001119823,0.0001496847],"domain_scores_gemma":[0.9980464,0.0006335766,0.0006266683,0.0002342837,0.0001225282,0.0003365904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.987847,0.001347612,0.0007788326,0.0005488726,0.002108741,0.00003045852,0.00001677738,0.0002495143,0.0008347924,0.00006671126,0.0003498137,0.005820881],"study_design_scores_gemma":[0.9706783,0.02397298,0.002539809,0.00003259959,0.001562272,0.00005075202,0.00001382693,0.0003343805,0.0002244009,0.0001718668,0.0004024903,0.00001629288],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818097,0.0092379,0.001059705,0.000705431,0.0005000698,0.002542156,0.001995505,0.0001372807,0.002012108],"genre_scores_gemma":[0.9908449,0.002280704,0.0009443541,0.0007223802,0.0003213161,0.001959778,0.001619115,0.00002091058,0.001286573],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005464082,"threshold_uncertainty_score":0.02321219,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0792212121238377,"score_gpt":0.436616696189183,"score_spread":0.3573954840653453,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}